Syna Therapeutics, a joint venture of Reig Jofre (member of CataloniaBio & HealthTech) and Leanbio, announces a global license agreement with Intas Pharmaceuticals Ltd. to commercialise its biosimilar drug LB-0702 for the treatment of haematology diseases.

Under the terms of the agreement, Intas will obtain exclusive licensing rights to market LB-0702 worldwide and Syna will develop, manufacture, and supply the drug to Intas and its subsidiaries. The subsidiary Accord Healthcare, one of the key players in the global biosimilars market, has a sales and distribution network in 85 countries.

Syna will start clinical trials of LB-0702 in 2023 with the support of its partners Leanbio and Reig Jofre. Leanbio's technology platforms will be used to develop and manufacture the biosimilar, along with the expertise and capacity of Reig Jofre's new plant in Barcelona, which specialises in sterile injectables and freeze-dried biopharmaceuticals.

"The signing of this agreement is one of Syna's most important milestones since the company was founded in 2018 and confirms that it is the company was founded in 2018 and confirms the growing interest of the pharmaceutical industry and health systems in biopharmaceutical

systems in biosimilar medicines" says Dr. Andreu Soldevila, co-founder and CEO of Syna. "This is a very satisfactory agreement because we believe that the biosimilar LB-0702 will have a very positive impact on health systems. In addition, the subsidiary Accord Healthcare is the ideal partner to commercialise our biosimilar in the global market," explains Soldevila.

Syna Therapeutics is a joint venture between Reig Jofre and Leanbio that develops high-quality biosimilars and innovative molecules to respond to the growing global demand for biologic treatments. Syna has extensive experience and know-how in biosimilar medicines, covering the entire value chain to bring them to patients: creation of the cell bank, pharmaceutical development of the finished product, industrial production and commercialisation or licensing agreements. Created in 2018, Syna is based at the Barcelona Science Park.